GenSight cleared by MHRA to begin phase I/II study of GS-030 gene therapy for retinitis pigmentosa Jan. 10, 2018 No Comments
Kala announces NDA acceptance for KPI-121 1%, phase III data for KPI-121 0.25% Jan. 8, 2018 No Comments
FDA issues complete response letter for Santen's NDA for intravitreal sirolimus Dec. 22, 2017 No Comments
FDA approves Luxturna gene therapy for biallelic RPE65 mutation-associated retinal dystrophy Dec. 20, 2017 No Comments
FDA Fast Track designation granted to elamipretide for Leber's hereditary optic neuropathy Dec. 19, 2017 No Comments
Netarsudil ophthalmic solution approved in the U.S. for lowering intraocular pressure Dec. 19, 2017 No Comments
RSS